GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » EPS without NRI

AEterna Zentaris (AEterna Zentaris) EPS without NRI

: $-3.48 (TTM As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

AEterna Zentaris's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.24. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.48.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for AEterna Zentaris's EPS without NRI or its related term are showing as below:

AEZS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -71.9   Med: 24.4   Max: 70.5
Current: 3.4

During the past 13 years, AEterna Zentaris's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 70.50% per year. The lowest was -71.90% per year. And the median was 24.40% per year.

AEZS's 3-Year EPS without NRI Growth Rate is ranked worse than
51.43% of 1295 companies
in the Biotechnology industry
Industry Median: 4.5 vs AEZS: 3.40

AEterna Zentaris's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.41.

AEterna Zentaris's EPS (Basic) for the three months ended in Dec. 2023 was $-1.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.41.


AEterna Zentaris EPS without NRI Historical Data

The historical data trend for AEterna Zentaris's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.17 -4.04 -1.87 -3.14 -3.48

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.87 -0.53 -0.85 -1.24

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's PE Ratio without NRI falls into.



AEterna Zentaris EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEterna Zentaris  (NAS:AEZS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


AEterna Zentaris EPS without NRI Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.